Lapatinib (CAS 231277-92-2) – Anticancer API

Lapatinib (CAS 231277-92-2) is a high-potency anticancer API classified as a dual tyrosine kinase inhibitor, specifically targeting EGFR and HER2 receptors. Its unique molecular structure enables it to block abnormal signal transduction in cancer cells, inhibiting proliferation and inducing apoptosis with high specificity. Produced through advanced precision synthesis, it maintains ultra-high purity and consistent bioactivity, fully complying with international pharmaceutical quality standards.

This premium API is a key raw material for pharmaceutical manufacturers developing targeted anticancer drugs. It is widely applied in formulating treatments for HER2-positive breast cancer, advanced gastric cancer, and other solid tumors, especially for patients with drug-resistant tumors. With proven clinical efficacy, favorable safety profile, and reliable stability, it meets the critical needs of targeted oncology drug R&D and production. For pharmaceutical enterprises and research institutions, it provides a trusted, high-performance solution to advance precision cancer therapy.